About IsoTherapeutics
IsoTherapeutics is a company based in Angleton (United States) founded in 2005 was acquired by Telix Pharma in February 2024. It operates as a Professional Services and Managed Services. IsoTherapeutics has raised $200 thousand across 5 funding rounds from investors including Telix Pharmaceuticals and OSTI.GOV. IsoTherapeutics offers products and services including Radiopharmaceutical Development, Conjugation Services, and Radiolabeling. IsoTherapeutics operates in a competitive market with competitors including Charles River Laboratories, Cytel, LabCorp, Precision Medicine Group and Frontage Laboratories, among others.
- Headquarter Angleton, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website isotherapeutics.com
- Social LinkedIn
- Acquired by Telix Pharma (Feb 2024)
- Legal Name Isotherapeutics Group, Llc
- Total Equity Funding$200K (USD)
in 5 rounds
- Latest Funding Round$200K (USD), Seed
Jan 2017
- InvestorsTelix Pharmaceuticals
& 1 more
- Acquired byTelix Pharma
(Feb 2024)
Products & Services of IsoTherapeutics
IsoTherapeutics offers a comprehensive portfolio of products and services, including Radiopharmaceutical Development, Conjugation Services, and Radiolabeling.
Services for radiopharmaceutical development are provided to clients.
Conjugation services for drug molecules are offered professionally.
Radiolabeling processes for pharmaceuticals are conducted with expertise.
Funding Insights of IsoTherapeutics
IsoTherapeutics has successfully raised a total of $200K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $200 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $200,000
- Total Rounds 5
- Last Round Seed — $200,000
- First Round $1.49M
(Mar 2010)
- Investors Count 1
All 5 funding rounds of IsoTherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in IsoTherapeutics
IsoTherapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Telix Pharmaceuticals and OSTI.GOV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Scientific and technical information is managed and disseminated by OSTI.GOV. | – | osti.gov | Oak Ridge, United States | |
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy. | 2015 | telixpharma.com | Melbourne, Australia |
Investor details for IsoTherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IsoTherapeutics
1 people are tracked at IsoTherapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Keith Frank | President, Chief Executive Officer, and co-founder | Leadership |
Complete people profiles for IsoTherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IsoTherapeutics
4 dated milestones of IsoTherapeutics across 19 years, from founding to its latest funding, stage changes and deals.
- Founded IsoTherapeutics is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Seed, of $200K.
- Exit Acquired by Telix Pharma.
Competitors of IsoTherapeutics
IsoTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Charles River Laboratories, Cytel, LabCorp, Precision Medicine Group and Frontage Laboratories, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| criver.com | 1947 | Wilmington, United States | – | 21,400 | Provider of drug discovery and preclinical development services | |
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| labcorp.com | 1969 | Burlington, United States | – | 9,321 | Provider of laboratory tests for physicians | |
| precisionmedicinegrp.com | 2012 | Bethesda, United States | $257.21M | 2,151 | Provider of clinical research, development, and commercialization services for life sciences | |
| frontagelab.com | 2001 | Exton, United States | $10.24M | – | Early drug development services are provided for pharma firms. | |
| precisionformedicine.com | 2013 | Bethesda, United States | $150M | – | Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices | |
| canopybiosciences.com | 2016 | St. Louis, United States | $4.48M | – | Cell line engineering services are offered via CRISPR-Cas9 technology. | |
| taimei.com | 2013 | Pleasanton, United States | $193.73M | – | A digital intelligence platform is focused on life sciences activities. | |
| scantox.com | 1977 | Lille Skensved, Denmark | $6.29M | 30 | Laboratory focused on providing pharmacology, toxicology, and histopathology services | |
| tenpointtherapeutics.com | 2020 | Cambridge, United Kingdom | $70M | – | Engineered cell-based therapeutics are developed to restore vision. |
Detailed competitors of IsoTherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Isotherapeutics
Complete news archive for IsoTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to IsoTherapeutics
10 companies that operate in the same segment as IsoTherapeutics (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about IsoTherapeutics
IsoTherapeutics was founded in 2005 and raised its 1st funding round 5 years after it was founded.
IsoTherapeutics is headquartered in Angleton, United States. It is registered at Angleton, Texas, United States.
IsoTherapeutics is a funded company, having raised a total of $200K across 5 funding rounds to date. The company's 1st funding round was a Grant of $1.49M, raised on Mar 2010.
IsoTherapeutics is involved in the development and manufacturing of radiopharmaceuticals for the pharmaceutical and life-science industries. Services provided include early-stage research, proof of concept for new chemistry or drug molecules, and production in cGMP facilities for preclinical studies. The company focuses on areas such as chelation, conjugation, kit development, radiolabeling, and analytical services. Collaboration with various organizations in the radiochemical and medical sectors is maintained to advance therapeutic and diagnostic agents for severe diseases. Facilities are equipped with state-of-the-art laboratories and equipment for radioanalytical counting and high-resolution gamma spectroscopy.
IsoTherapeutics's top competitors include LabCorp, Charles River Laboratories and Cytel.
IsoTherapeutics offers Radiopharmaceutical Development, Conjugation Services, and Radiolabeling.
IsoTherapeutics has 2 investors. Key investors include Telix Pharmaceuticals, and OSTI.GOV.
IsoTherapeutics operates through Isotherapeutics Group, Llc.
Yes. IsoTherapeutics was acquired by Telix Pharma in February 2024.